Advertisement

MiR-181a, a new regulator of TGF-β signaling, can promote cell migration and proliferation in gastric cancer

  • Shaohua Ge
  • Haiyang Zhang
  • Ting Deng
  • Wu Sun
  • Tao Ning
  • Qian Fan
  • Yi Wang
  • Xinyi Wang
  • Qiumo Zhang
  • Zhengyang Zhou
  • Haiou Yang
  • Guoguang Ying
  • Yi Ba
PRECLINICAL STUDIES
  • 39 Downloads

Summary

Transforming growth factor-beta (TGF-β) signaling pathway plays pivotal roles in various types of cancer. TGF-β receptor 2 (TGFβR2) contains a kinase domain that phosphorylates and activates the downstream of the TGF-β signaling pathway. Our previous microarray analysis revealed marked changes in miR-181a expression in gastric cancers, and the bioinformatics analysis suggested that miR-181a negatively regulated TGFβR2. In order to verify the effect of miR-181a on TGFβR2 and clarify the influence of miR-181a on the migration and proliferation of gastric cancer, studies in gastric cancer cell lines and xenograft mouse models were carried out. We found that a reduced expression of TGFβR2 and an increased expression miR-181a in gastric cancer tissues compared to adjacent noncancerous tissues. A luciferase reporter assay confirmed that TGFβR2 was a target of miR-181a. In addition, we found that miR-181a mimics, which increased the level of miR-181a, downregulated the expression of TGFβR2 in the gastric cancer cell line SGC-7901. Moreover, both the overexpression of miR-181a and the downregulation of TGFβR2 promoted the migration and proliferation of SGC-7901 cells. Conversely, SGC-7901 cell migration and proliferation were inhibited by the downregulation of miR-181a and the overexpression of TGFβR2. Furthermore, the increased expression of miR-181a and the decreased expression of TGFβR2 also enhanced the tumor growth in mice bearing gastric cancer. Our results herein indicated that miR-181a promoted the migration and proliferation of gastric cancer cells by downregulating TGFβR2 at the posttranscriptional level. The present study suggests that miR-181a is a novel negative regulator of TGFβR2 in the TGF-β signaling pathway and thus represents a potential new therapeutic target for gastric cancer.

Keywords

TGFβR2 miR-181a Gastric cancer Posttranscriptional regulation Molecular targeted therapy 

Abbreviations

3’-UTR

3′-untranslated region

CCK-8

Cell Counting Kit-8

cDNA

complementary deoxyribonucleic acid

EdU

5-ethynyl-2-deoxyuridine

HER-2

epidermal growth factor receptor-2

miRNA

microRNA

RT-qPCR

real-time quantitative polymerase chain reaction

siRNA

small interfering RNA

TGF-β

transforming growth factor-beta

TGFβR2

TGF-β receptor 2

Notes

Author contributions

SG and HZ performed most of the experiments, analyzed the data, and wrote the manuscript. TD, WS and TN reviewed and edited the manuscript. QF performed some experiments. YB and GY designed the experiments and edited the manuscript. YB is the guarantor of this work and has unlimited access to all of the data in the study and thus takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding information

This work was supported by the National Natural Science Foundation of China (nos. 81,772,629, 81,602,158, 81,602,156, 81,702,275 and 81,702,437) and the Tianjin Health and Family Planning Commission Foundation of Science and Technology (no. 15KG142).

Compliance with ethical standards

Ethics approval and consent to participate

Animal care and experiments were performed in accordance with guidelines of the Institutional Animal Use Committee of Tianjin Medical University, and the procedures were approved by the Institutional Animal Care and Use Committee.

Consent for publication

Written informed consent for publication was obtained from all participants.

Competing interests

The authors have no competing interests to declare.

References

  1. 1.
    Katz LH, Likhter M, Jogunoori W, Belkin M, Ohshiro K, Mishra L (2016) TGF-beta signaling in liver and gastrointestinal cancers. Cancer Lett 379(2):166–172PubMedPubMedCentralGoogle Scholar
  2. 2.
    Liu S, Chen S, Zeng J (2018) TGFbeta signaling: a complex role in tumorigenesis (review). Mol Med Rep 17(1):699–704PubMedGoogle Scholar
  3. 3.
    Shukla SK, Khatoon J, Prasad KN, Rai RP, Singh AK, Kumar S, Ghoshal UC, Krishnani N (2015) Transforming growth factor beta 1 (TGF-beta1) modulates Epstein-Barr virus reactivation in absence of Helicobacter pylori infection in patients with gastric cancer. Cytokine 77:176–179PubMedGoogle Scholar
  4. 4.
    Sun N, Xue Y, Dai T, Li X, Zheng N (2017) Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-beta signaling. Biosci Rep 37(4)Google Scholar
  5. 5.
    Lee HJ, Park JM, Hahm KB (2016) Role of inhibitory transforming growth factor-beta signal Smad7 in helicobacter pylori-associated gastric damage. Korean J Gastroenterol 68(4):186–194PubMedGoogle Scholar
  6. 6.
    Jin B, Liu Y, Wang H (2016) Antagonism of miRNA-21 sensitizes human gastric Cancer cells to paclitaxel. Cell Biochem Biophys 72(1):275–282Google Scholar
  7. 7.
    Wang P, Li Z, Liu H, Zhou D, Fu A, Zhang E (2016) MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun 479(1):91–96PubMedGoogle Scholar
  8. 8.
    Eto K, Iwatsuki M, Watanabe M, Ida S, Ishimoto T, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Baba H (2013) The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol 21(1):343–350PubMedGoogle Scholar
  9. 9.
    Chang H, Kim N, Park JH, Nam RH, Choi YJ, Park SM, Yoon H, Shin CM, Lee DH (2015) Helicobacter pylori might induce TGF-beta1-mediated EMT by means of cagE. Helicobacter 20(6):438–448PubMedGoogle Scholar
  10. 10.
    Wang WW, Yuan XL, Chen H, Xie GH, Ma YH, Zheng YX, Zhou YL, Shen LS (2015) CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. Oncotarget 6(32):33486–33499PubMedPubMedCentralGoogle Scholar
  11. 11.
    Hu WQ, Wang LW, Yuan JP, Yan SG, Li JD, Zhao HL, Peng CW, Yang GF, Li Y (2014) High expression of transform growth factor beta 1 in gastric cancer confers worse outcome: results of a cohort study on 184 patients. Hepato-Gastroenterology 61(129):245–250PubMedGoogle Scholar
  12. 12.
    Kim YW, Park J, Lee HJ, Lee SY, Kim SJ (2012) TGF-beta sensitivity is determined by N-linked glycosylation of the type II TGF-beta receptor. Biochem J 445(3):403–411PubMedPubMedCentralGoogle Scholar
  13. 13.
    Kim WS, Park C, Hong SK, Park BK, Kim HS, Park K (2000) Microsatellite instability (MSI) in non-small cell lung cancer (NSCLC) is highly associated with transforming growth factor-beta type II receptor (TGF-beta RII) frameshift mutation. Anticancer Res 20(3A):1499–1502PubMedGoogle Scholar
  14. 14.
    Guo W, Dong Z, Guo Y, Chen Z, Yang Z, Kuang G (2011) Association of polymorphisms in transforming growth factor-beta receptors with susceptibility to gastric cardia adenocarcinoma. Mol Biol Rep 39(4):4301–4309PubMedGoogle Scholar
  15. 15.
    Duan J, Zhang H, Qu Y, Deng T, Huang D, Liu R, Zhang L, Bai M, Zhou L, Ying G, Ba Y (2016) Onco-miR-130 promotes cell proliferation and migration by targeting TGFbetaR2 in gastric cancer. Oncotarget 7(28):44522–44533PubMedPubMedCentralGoogle Scholar
  16. 16.
    Fragoso R, Mao T, Wang S, Schaffert S, Gong X, Yue S, Luong R, Min H, Yashiro-Ohtani Y, Davis M, Pear W, Chen CZ (2012) Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1. PLoS Genet 8(8):e1002855PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ma YY, Tao HQ (2012) Microribonucleic acids and gastric cancer. Cancer Sci 103(4):620–625PubMedGoogle Scholar
  18. 18.
    Strotbek M, Schmid S, Sanchez-Gonzalez I, Boerries M, Busch H, Olayioye MA (2017) miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. Int J Cancer 140(10):2310–2320PubMedGoogle Scholar
  19. 19.
    Cai ZG, Zhang SM, Zhang H, Zhou YY, Wu HB, Xu XP (2013) Aberrant expression of microRNAs involved in epithelial-mesenchymal transition of HT-29 cell line. Cell Biol Int 37(7):669–674PubMedGoogle Scholar
  20. 20.
    Liu J, Wu CP, Lu BF, Jiang JT (2014) Mechanism of T cell regulation by microRNAs. Cancer Biol Med 10(3):131–137Google Scholar
  21. 21.
    Chen Z, Wu L, Lin Q, Shi J, Lin X, Shi L (2016) Evaluation of miR-182/miR-100 ratio for diagnosis and survival prediction in bladder cancer. Arch Iran Med 19(9):645–651PubMedGoogle Scholar
  22. 22.
    Park SK, Park YS, Ahn JY, Do EJ, Kim D, Kim JE, Jung K, Byeon JS, Ye BD, Yang DH, Park SH, Hwang SW, Jung HY, Myung SJ (2016) MiR 21-5p as a predictor of recurrence in young gastric cancer patients. J Gastroenterol Hepatol 31(8):1429–1435PubMedGoogle Scholar
  23. 23.
    Jiang C, Fang X, Zhang H, Wang X, Li M, Jiang W, Tian F, Zhu L, Bian Z (2017) Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro. Tumour Biol 39(4):1010428317697556PubMedGoogle Scholar
  24. 24.
    Yang F, Liu X, Liu Y, Zhang C, Wang Z, Jiang T, Wang Y (2017) miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-kappaB pathways in glioblastoma. Cancer Lett 396:1–9PubMedGoogle Scholar
  25. 25.
    Liu YS, Lin HY, Lai SW, Huang CY, Huang BR, Chen PY, Wei KC, Lu DY (2017) MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Oncogene 36(35):5006–5022PubMedGoogle Scholar
  26. 26.
    Butrym A, Rybka J, Baczynska D, Poreba R, Mazur G, Kuliczkowski K (2016) Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia. Oncol Lett 12(4):2296–2300PubMedPubMedCentralGoogle Scholar
  27. 27.
    Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D'Incalci M, Romualdi C, Marchini S (2016) Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol 27(4):625–634PubMedGoogle Scholar
  28. 28.
    Tian F, Shen Y, Chen Z, Li R, Lu J, Ge Q (2016) Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene 591(2):338–343PubMedGoogle Scholar
  29. 29.
    Liu J, Xing Y, Rong L (2018) miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep 39(4):1631–1639PubMedPubMedCentralGoogle Scholar
  30. 30.
    Cho JH, Lim JY, Cho JY (2017) Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World J Gastroenterol 23(41):7407–7414PubMedPubMedCentralGoogle Scholar
  31. 31.
    Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabo A, Gyorffy B (2016) Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7(31):49322–49333PubMedPubMedCentralGoogle Scholar
  32. 32.
    Shi Q, Zhou Z, Ye N, Chen Q, Zheng X, Fang M (2017) MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. Cancer Biomark 20(4):539–546PubMedGoogle Scholar
  33. 33.
    Weidle UH, Birzele F, Kollmorgen G, Nopora A (2017) Potential microRNA-related targets for therapeutic intervention with ovarian Cancer metastasis. Cancer Genomics Proteomics 15(1):1–15PubMedCentralGoogle Scholar
  34. 34.
    Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K (2010) The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res 71(4):1442–1453PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Shaohua Ge
    • 1
  • Haiyang Zhang
    • 1
  • Ting Deng
    • 1
  • Wu Sun
    • 1
  • Tao Ning
    • 1
  • Qian Fan
    • 1
  • Yi Wang
    • 1
  • Xinyi Wang
    • 1
  • Qiumo Zhang
    • 1
  • Zhengyang Zhou
    • 1
  • Haiou Yang
    • 1
  • Guoguang Ying
    • 1
  • Yi Ba
    • 1
  1. 1.Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical UniversityTianjinChina

Personalised recommendations